Drug intelligence / Profile preview

RS-0461 (PDC Therapeutics)

Development stage: Preclinical
Lead developer: PDC Therapeutics
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

RS-0461 is a preclinical-stage polymer-drug conjugate (PDC) being developed by PDC Therapeutics for the treatment of ovarian cancer. Utilizing a proprietary polymer-based delivery platform, RS-0461 is designed to function as a targeted chemotherapy, delivering a cytotoxic payload directly to tumor cells to enhance efficacy while reducing systemic toxicity. This approach is conceptually similar to antibody-drug conjugates (ADCs) but employs a synthetic polymer as the delivery vehicle instead of a monoclonal antibody. As of the current reporting, the specific molecular target and the identity of the chemotherapeutic payload remain undisclosed by the developer.

Beyond the preview

Go deeper on RS-0461 (PDC Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-0461 (PDC Therapeutics).

Explore the full profile